169 related articles for article (PubMed ID: 8602867)
1. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.
Bridges EG; Dutschman GE; Gullen EA; Cheng YC
Biochem Pharmacol; 1996 Mar; 51(6):731-6. PubMed ID: 8602867
[TBL] [Abstract][Full Text] [Related]
2. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.
Cui L; Schinazi RF; Gosselin G; Imbach JL; Chu CK; Rando RF; Revankar GR; Sommadossi JP
Biochem Pharmacol; 1996 Nov; 52(10):1577-84. PubMed ID: 8937473
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
J Med Chem; 1994 Mar; 37(6):798-803. PubMed ID: 8145230
[TBL] [Abstract][Full Text] [Related]
5. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.
Gosselin G; Schinazi RF; Sommadossi JP; Mathé C; Bergogne MC; Aubertin AM; Kirn A; Imbach JL
Antimicrob Agents Chemother; 1994 Jun; 38(6):1292-7. PubMed ID: 8092827
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
Biochem Pharmacol; 1994 Jan; 47(2):171-4. PubMed ID: 8304960
[TBL] [Abstract][Full Text] [Related]
7. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
8. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.
Schinazi RF; Schlueter-Wirtz S; Stuyver L
Antivir Chem Chemother; 2001; 12 Suppl 1():61-5. PubMed ID: 11594690
[TBL] [Abstract][Full Text] [Related]
9. Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.
Schinazi RF; Gosselin G; Faraj A; Korba BE; Liotta DC; Chu CK; Mathé C; Imbach JL; Sommadossi JP
Antimicrob Agents Chemother; 1994 Sep; 38(9):2172-4. PubMed ID: 7811039
[TBL] [Abstract][Full Text] [Related]
10. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
13. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
Watanabe KA; Harada K; Zeidler J; Matulic-Adamic J; Takahashi K; Ren WY; Cheng LC; Fox JJ; Chou TC; Zhu QY
J Med Chem; 1990 Aug; 33(8):2145-50. PubMed ID: 1695683
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs.
Faraj A; Agrofoglio LA; Wakefield JK; McPherson S; Morrow CD; Gosselin G; Mathe C; Imbach JL; Schinazi RF; Sommadossi JP
Antimicrob Agents Chemother; 1994 Oct; 38(10):2300-5. PubMed ID: 7530932
[TBL] [Abstract][Full Text] [Related]
16. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
17. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA
Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Heredia A; Davis C; Redfield R
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):246-55. PubMed ID: 11115955
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides.
Sterzycki RZ; Ghazzouli I; Brankovan V; Martin JC; Mansuri MM
J Med Chem; 1990 Aug; 33(8):2150-7. PubMed ID: 2165162
[TBL] [Abstract][Full Text] [Related]
20. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.
Daluge SM; Purifoy DJ; Savina PM; St Clair MH; Parry NR; Dev IK; Novak P; Ayers KM; Reardon JE; Roberts GB
Antimicrob Agents Chemother; 1994 Jul; 38(7):1590-603. PubMed ID: 7526782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
